Literature DB >> 3308225

Malaria specific human T cell clones: crossreactivity with various plasmodia species.

P Simitsek1, C Chizzolini, L Perrin.   

Abstract

Peripheral blood mononuclear cells (PBMC) from donors with or without previous exposure to malaria in vivo were cultivated for 4 to 7 days in the presence of different malaria antigen (M.Ag) preparations: Plasmodium falciparum (P.f.Ag), P. berghei (P.b.Ag) and P. gallinaceum (P.g.Ag). All preparations induced a proliferative response in PBMC from donors with or without previous exposure to malaria. PBMC from both groups of donors were then primed with each of the three M.Ag and cloned in presence of autologous irradiated PBMC and M.Ag. All 152 clones recovered had the T4+ phenotype and required autologous antigen presenting cells (APC) in addition to M.Ag for proliferation. Species specific and crossreactive T cell clones (T cell clones proliferating in the presence of the three M.Ag preparations) were recovered following priming with each of the three M.Ag. Species specific and crossreactive T cell clones were recovered in similar percentages (approximately 50%) using PBMC from donors with or without previous exposure to malaria. These data are discussed in the context of crossreactivity at the T cell level among various plasmodia species and in relation to epitope recognition of malaria native, synthetic and fusion polypeptides.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3308225      PMCID: PMC1542396     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  Nonsterilizing immunity in avian malaria: an antibody-independent phenomenon.

Authors:  R G Rank; W P Weidanz; A Bondi
Journal:  Proc Soc Exp Biol Med       Date:  1976-02

2.  Partial characterization of a malaria mitogen.

Authors:  B M Greenwood; A J Oduloju; T A Platts-Mills
Journal:  Trans R Soc Trop Med Hyg       Date:  1979       Impact factor: 2.184

3.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

4.  Primary sensitisation and restimulation of human lymphocytes with soluble antigen in vitro.

Authors:  E J Hensen; B G Elferink
Journal:  Nature       Date:  1979-01-18       Impact factor: 49.962

5.  In vitro primary immunization of human peripheral blood lymphocytes to KLH: evidence for HLA-D region restriction.

Authors:  G E Rodey; L K Luehrman; D W Thomas
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

6.  Lymphocyte transformation in human Plasmodium falciparum malaria.

Authors:  D J Wyler; J J Oppenheim
Journal:  J Immunol       Date:  1974-08       Impact factor: 5.422

7.  Detection of malarial antibodies in man by fluorescent antibody test using Plasmodium gallinaceum as antigen.

Authors:  P L Giacometti; V Suter-Kopp
Journal:  Acta Trop       Date:  1973       Impact factor: 3.112

Review 8.  Immunity to malaria.

Authors:  S Cohen
Journal:  Proc R Soc Lond B Biol Sci       Date:  1979-01-15

9.  Human malaria parasites in continuous culture.

Authors:  W Trager; J B Jensen
Journal:  Science       Date:  1976-08-20       Impact factor: 47.728

10.  Mitogenic activity of extracts from continuous cultures of Plasmodium falciparum.

Authors:  A A Gabrielsen; J B Jensen
Journal:  Am J Trop Med Hyg       Date:  1982-05       Impact factor: 2.345

View more
  2 in total

1.  Interactions of CD4+ and CD8+ human T lymphocytes from malaria-unprimed donors with Plasmodium falciparum schizont stage.

Authors:  C Roussilhon; M Agrapart; C Behr; P Dubois; J J Ballet
Journal:  J Clin Microbiol       Date:  1989-11       Impact factor: 5.948

2.  Human TcR gamma delta+ lymphocyte response on primary exposure to Plasmodium falciparum.

Authors:  C Roussilhon; M Agrapart; P Guglielmi; A Bensussan; P Brasseur; J J Ballet
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.